Novo Nordisk weight-loss drug trials

#PRESS: At #ADA2025, Novo Nordisk is sharing the full phase 3 study results in people with overweigh or obesity, and overweight or obesity and type 2 diabetes respectively. Both studies simultaneously published in The New England Journal of Medicine. Read the full press release

#PRESS: In connection with #ADA2025, Novo Nordisk is sharing new subcutaneous and oral product data in people living with obesity, also published in The Lancet. Read the full press release.

P3 CagriSema in adults with overweight #obesity Placebo subtracted #weightloss of 17.3%; 60.2% & 40.4% achieved 20% and 25% weight loss, respectively @AmDiabetesAssn #ADA2025 www.nejm.org/doi/full/10.1056/NEJMoa2502081

Novo Nordisk’s next-gen obesity drug results a letdown for investors, but not physicians, ⁦@elaineywchen⁩ writes. www.statnews.com/2025/06/22/novo-nordisk-cagrisema-weight-loss-drug-comparison-eli-lilly-zepbound-investors-disappointed/